TissueGen to expand spinal cord injury repair program — 5 key updates

Spinal Tech

TissueGen now has a senior scientist position to manage the company's spinal cord injury repair program.

"2014 has been an exciting year for us in terms of fielding our technology and really exploring how ELUTE fiber can be used to advance nerve repair and regenerative medicine," said Christopher Knowles, president and CEO of TissueGen. "We have made great strides in our research and development efforts to validate the benefits of our novel method of drug and growth factor delivery and we expect to accelerate these advancements in 2015."

 

Here are five updates from the company:

 

1. TissueGen expects to grow its core team by as much as 50 percent through advancing spinal cord injury repair and regenerative medicine applications.

 

2. Mario Romero-Ortega, MD, of the University of Texas at Dallas, demonstrated a model for nerve regeneration last year at Neuroscience 2014 that uses both TissueGen's ELUTE fibers and its licensed, patent-pending technology for creating chemical gradients. This model could improve nerve repair strategies and function recovery for paralysis patients without tissue harvesting elsewhere in the patient's body.

 

3. The company received a patent for its self-anchoring ARCHER stent with drug delivery capabilities to allow devices to stay in place when implanting tubular organs.

 

4. Last year the company completed several facility upgrade projects, including:

 

• Installing a Class 10,000 clean room facility
• Investing in major information technology upgrades
• Acquired manufacturing and development laboratory tools

 

5. There were several exhibits last year at professional meetings and events focused on the company's products.

 

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Podcast

Featured Whitepapers